Healio
Healio
ASCO Prostate Cancer take homes collection banner

Take Homes in Prostate Cancer
ByDavid Statman

Read more

June 22, 2022
3 min watch
Save

VIDEO: PROpel, MAGNITUDE studies provide promise for PARP inhibitors for prostate cancer

ByDavid Statman

In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses recent developments related to PARP inhibitors and their effect on prostate cancer presented at ASCO Annual Meeting.

Dorff first examines the PROpel and MAGNITUDE studies, which showed positive results and raised the possibility that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib could have broader application in unselected molecular populations.

Dorff also touches on the BREAKAWAY study presented by Maha Hussain, MD, which looks to clear up confusion on how to use abiraterone.

References:

  • Saad F, et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
  • Chi K, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Sources/Disclosures

Collapse
Source: Healio Interview
Disclosures: Dorff reports consulting for Astellas, AstraZeneca, Janssen, Pfizer and Seagen.

Read more about

prostate cancer
 

Related Content